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Executive Summary 
Uninsured and underinsured people living with Human Immunodeficiency 
Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS) are able to utilize 
federally funded AIDS Drug Assistance Programs (ADAPs) to cover the price of their 
HIV-related medications. In Kentucky, this program also provides support services 
through social workers, a dedicated pharmacist, and medications by mail order.  
With the Affordable Care Act, many patients previously covered by the Kentucky 
AIDS Drug Assistance Program (KADAP) will be newly eligible for Medicaid and will 
no longer receive services through KADAP.  There is concern that people in this 
situation will be at a disadvantage without these services and, in turn, be less 
adherent to their medications. People living with HIV/AIDS should regularly take 
≥95% of their medications in order to prevent medication resistance and disease-
related morbidity and mortality,   
 
The purpose of this study is to determine the average medication adherence of 
patients in KADAP and Kentucky Medicaid, evaluate whether people enrolled in 
Medicaid have significantly lower adherence compared to KADAP, and determine if 
any demographic variables are associated with medication nonadherence in either 
program through multivariate regression.  With this information, recommendations 
will be made regarding what can be done from programmatic and policy 
standpoints to increase medication adherence in this population. 
 
Pharmacy claims and demographic data were collected from the Kentucky Clinic 
Pharmacy and the Bluegrass Care Clinic at the University of Kentucky for all of 2011. 
Medication adherence was calculated using the medication possession ratio (MPR), 
which calculates the percentage of time the patient has their medications on hand 
each month based on pharmacy claims data.  The average MPR for KADAP patients 
is 84.7% (n=2,2024; range: 14.9%-100%) and the average MPR for Medicaid 
patients is 77.3% (n=55; range: 16.4%-100%).  When KADAP and Medicaid data 
were combined, 3 variables were significantly associated with MPR in multivariate 
regression: age (coef: 0.123, p<0.001), black race (coef: -3.8, p<0.001), and Medicaid 
enrollment (coef: -6.23, p<0.001).  Similar significant was found with KADAP alone, 
but not with Medicaid. 
 
Younger, black KADAP patients tend to have lower MPRs and Kentucky Medicaid 
patients have significantly lower MPRs than KADAP patients. In order to increase 
adherence, the policy regarding Medicaid and KADAP co-enrollment should be 
changed to allow newly eligible Medicaid patients to continue using KADAP’s 
services without financial need.  Additionally, pharmacy call lists could be made, 
with priority on younger, black KADAP patients, for refill reminders and to open 
dialogue between the patient and the pharmacist regarding medication concerns. 
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Background 
Section 1: HIV and Medication Adherence 
  
Human Immunodeficiency Virus (HIV) and Acquired Immune Deficiency 
Syndrome (AIDS) 
 
 Human Immunodeficiency Virus (HIV) is a retrovirus that attacks certain 
immune system cells (CD4 or T cells) and decreases the body’s ability to fight off 
infections.  Once a patient is infected with HIV, he or she is infected for life. The 
diagnosis of Acquired Immune Deficiency Syndrome (AIDS) is given when an HIV-
positive patient’s CD4 cell count drops below 200 cells/mL or when a patient with 
HIV acquires a certain “AIDS-defining” condition, including opportunistic infections 
and cancers. HIV is transmitted through the blood, semen, genital fluids, or breast 
milk of an individual infected with the virus and is most commonly transmitted 
through unprotected sexual contact or sharing needles and syringes. 1  
 The prognosis of an HIV-infected individual has greatly improved since the 
initial outbreak of the virus due to the use of highly active antiretroviral therapy 
(HAART), which is a combination of specific antiretroviral medications usually 
composed of three medications from varying drug classes.2 Due to these 
medications and increased awareness of the disease, the age-adjusted HIV death 
rate has dropped by 80 percent since its peak in 1995, including an 11 percent drop 
between 2007 and 2008.3,4 Additionally, antiretroviral treatment (ART) has been 
shown to significantly reduce the risk of transmission of the disease giving the 
patient the possibility of having an undetectable viral load (amount of virus in 
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blood).5  However, even with these medications, it has been shown that only one-
quarter of the 1.1 million Americans living with HIV have their virus under control, 
with only 37 percent of HIV patients remaining in regular care.6   
Section 2: Literature Review 
Medication Adherence in HIV-positive Patients 
 
 Research has shown that patients typically take a much lower percentage of 
their medications than is required to successfully suppress viral replication.  In a 
2006 study by Gross and colleagues, researchers assessed the magnitude of 
antiretroviral therapy adherence (based on pharmacy refill data) needed to 
maintain HIV suppression in patients who had already achieved initial viral 
suppression.  The study assessed a population-based cohort of 1,634 patients who 
had at least 2 consecutive viral loads less than 500 copies/mL and had prescriptions 
filled at least 3 times during the follow-up period.  It was found that patients with 
less than 95 percent adherence were 1.66 times more likely to experience 
virological failure (2 consecutive viral loads greater than 1000 copies/mL) than 
those with greater than 95 percent adherence.7   In a 2005 retrospective audit study 
by Fairley and colleagues, self-reported adherence and pharmacy records were used 
to determine adherence and compared to the patient’s viral load.  The study found 
that the proportion of patients with viral load below 400 copies/mL fell below 60 
percent when adherence fell below 95 percent (by pharmacy record) and 97 
percent (by self-report).  The study also found that adherence increased 
significantly each year, and adherence was significantly higher for once a day 
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compared with twice a day treatment.8  In a 2000 prospective, observational study 
by Paterson and colleagues, 81 patients were studied in order to assess the effects of 
different levels of adherence (measured by the Medication Events Monitoring 
System) to therapy on virologic, immunologic, and clinical outcomes.  The study 
found that patients with 95 percent or greater adherence had better virologic 
outcomes, a greater increase in CD4 lymphocyte count, and a lower hospitalization 
rate than patients with lower levels of adherence.9 Prior to this study, 80 percent 
adherence was typically regarded as the threshold for better outcomes among 
patients, highlighting the importance of adherence for HIV patients in order to 
optimize their overall health and survival.   
Overall, a high level of medication adherence is imperative in HIV patients in order 
to maintain viral suppression and prevent medication resistance, transmission of 
resistant viruses, AIDS-related morbidity, mortality, and hospitalizations.9,10  In a 
recent study by Montaner and colleagues, the increased use of HAART in British 
Columbia between 1996 and 2012 was associated with increasing virological 
suppression and decreasing drug resistance.10  Additionally, AIDS incidence 
decreased by 80 percent (p=0.330), HIV mortality decreased 80 percent (p=0.0115), 
and new HIV diagnoses decreased by 66 percent (p=0.0004).  Their models 
predicted that for every increase of 100 individuals on HAART, the estimated HIV 
incidence decreased 1.2 percent and for every 1 percent increase in the number of 
individuals suppressed on HAART, the estimated HIV incidence also decreased by 1 
percent.  
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Risk Factors for Nonadherence in HIV-positive Patients 
 
 Several studies have been completed to determine which characteristics put 
a patient at increased risk of having a low rate of adherence and, therefore, 
suboptimal health outcomes.  In a 2007 prospective, cross-sectional, observational 
study by Barclay and colleagues, 185 HIV-positive adults were studied to determine 
age-associated predictors of medication adherence.11 The study found that HIV-
infected adults aged 50 and older were twice as likely to achieve a 95 percent 
adherence rate than were younger HIV-positive participants and that, among the 
older age group, neurocognitive functioning was the sole significant predictor of 
medication adherence.  Poor adherence among younger HIV-positive participants 
was associated with current drug abuse/dependence and a lack of independent 
financial resources.  In a 1999 cross-sectional study by Gordillo and colleagues, 
sociodemographic and psychological factors that influence adherence were assessed 
by patient self-report and pill count.12 Based on the multivariate analysis, subjects 
aged 32-35 years, who were not intravenous drug users, had CD4 cell counts from 
200-499 cells/mL at enrollment, were not depressed, and with self-perceived good 
social support had better adherence to antiretroviral therapy.  In the study 
previously discussed by Gross and colleagues, patients with greater than 95 percent 
adherence were less likely to be injection drug users, were less likely to have 
received a protease inhibitor in the first regimen (a specific type of antiretroviral 
contained in HAART), were slightly older, and were more likely to have received 
follow-up from physicians with more HIV-1 treatment experience than subjects with 
less than 95 percent adherence.  Additionally, the study found that being an 
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injection user at any time, younger age, and higher baseline CD4 cell count were 
significantly associated with the likelihood of virological failure, irrespective of 
adherence.     
A 2011 prospective cohort study done by Godwin and colleagues from the 1917 
Infectious Diseases Clinic at the University of Alabama – Birmingham studied 
medication adherence specifically for patients enrolled in their state’s AIDS Drug 
Assistance Program using medication possession ratio (a ratio of how often a 
patient has their medication on-hand calculated by pharmacy claims data).13 Using 
multivariate ordinal logistic regression, the study found that certain patient 
characteristics, including younger age, nonwhite males, lower CD4 count, and a 
history of alcohol abuse, were associated with poor medication adherence. The 
study also found that approximately 25 percent of the patients had a medication 
possession ratio of less than 69 percent, while the optimal medication possession 
ratio is greater than 95 percent. 
Section 3: Public Programs for Patients with HIV/AIDS 
Ryan White Program 
 
The Ryan White Program is the largest federal program designed specifically for 
individuals living with HIV in the United States and is estimated to reach 
approximately half a million people each year.14 The namesake of the program was 
diagnosed with AIDS at age 13 from his hemophilia treatment and was then 
ostracized from his school due to a lack of education about the disease among school 
officials and the community.15  Subsequently, he and his mother championed for 
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HIV/AIDS research and public education about the disease, which led to the 
formation and passing of the Ryan White Comprehensive AIDS Resources 
Emergency (CARE) Act.  The program provides care and support services to 
individuals and families affected by the disease and operates as the “payer of last 
resort” by acting as a financial safety net for patients who have no source of 
coverage or are otherwise unable to pay.14 
The program is administered by the Health Resources and Services Administration 
(HRSA) and is the third largest source of federal funding for HIV care in the U.S. after 
Medicare and Medicaid.14 
AIDS Drug Assistance Programs (ADAPs) 
 
The Ryan White Program consists of several parts and states, cities, and other 
organizations apply for funding by part.  Part B, which provides grants to states and 
U.S. Territories to improve the quality, availability, and organization of HIV/AIDS 
health care and support services, has funds earmarked by Congress specifically for 
ADAPs.14,16  ADAPs provide medications for the treatment of HIV and program funds 
may also be used for services that enhance different aspects of drug treatments, 
including medication adherence .16  Each state must establish its own eligibility 
criteria for ADAP and each state is required to make patients recertify every 6 
months16.  It has been reported that ADAP provides care to one-third of people 
living with HIV and demand is increasing as people with HIV are living longer.17,18  
In FY2013, ADAP’s budget was $2.01 billion but the program still required an 
additional $75 million of emergency funding, which it also received in FY2012.18 The 
emergency funding was given to the states to help eliminate some of the cost-
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containment measures that had been put into place, including waiting lists and 
restricted forumlaries.18 However, many states still have these cost-containment 
measures in place due to funding issues.  Although funding for the program has 
increased over time, when adjusted for inflation, FY2012 funding is at the same level 
as it was last decade, despite an increase in the number of people living with HIV.19  
Kentucky AIDS Drug Assistance Program (KADAP) 
 
In Kentucky, in order to participate in ADAP, residents must have documented 
HIV/AIDS, have an income less than 300 percent of the Federal Poverty level, and 
not be 100 percent by another third party payer.  The Kentucky Clinic Pharmacy at 
the University of Kentucky is the contract pharmacy for KADAP and all KADAP 
enrollees must have their KADAP-covered medications filled exclusively at this 
pharmacy.  The Kentucky Clinic Pharmacy provides several services to these 
patients, including preparation and dispensing of KADAP formulary medications, 
counseling and education services, compliance counseling and tracking, and mail 
order service for medication delivery.20 The pharmacy employs one pharmacist and 
one technician who are dedicated to providing these services to KADAP patients.  
Patients are limited to receiving a quantity of medication to last 30 days at a time, 
and any patients not having any medication refilled for 90 days have their accounts 
placed on hold.  Although the pharmacy does refill prescription automatically, a 
reorder reminder notice is provided with each filled prescription.   
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Affordable Care Act (ACA) 
 
With the implementation of the Patient Protection and Affordable Care Act, it is 
difficult to determine how the Ryan White Program and, consequently, ADAP will be 
affected.  Since states can opt-in for Medicaid expansion, which will include 
additional HIV patients who did not previously qualify for Medicaid, it is unknown 
whether the Ryan White Program and ADAP will continue as they currently 
function.  However, a recent study involving 15 states showed that only 21 percent 
of Medicaid patients with HIV were linked to appropriate care within one year of 
their diagnosis.21 The National Alliance of State and Territorial AIDS Directors 
(NASTAD) suggests that the Ryan White program will still be needed to fill gaps in 
covered services and populations and continue support services even after the full 
implementation of ACA22.  In addition, 70 percent of Ryan White program clients 
have public or private insurance coverage, indicating that having insurance 
coverage is not always sufficient enough to aid in the cost of HIV-related care.14,23  
The Ryan White program would also continue to provide adherence, linkage, and 
retention services that would not be included in the ACA.17  Since Medicaid does not 
provide the same services as ADAP (including additional pharmacy services, access 
to social workers, and retention services), it is unknown how the Medicaid 
expansions will affect patients who are newly eligible for Medicaid and no longer 
eligible for ADAP.  
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Section 4: Problem Statement 
 
With this information, there are two main problems that need to be addressed.  The 
first problem is that there are many barriers to adherence for HIV patients in either 
KADAP or Medicaid that can be improved upon in order to increase their medication 
adherence and program utilization.  These barriers are important to consider in 
order to decrease disease-related morbidity and mortality, decrease transmission of 
the disease, and prevent medication resistance.  Additionally, since many states 
have waiting lists, it is important for patients who are in the program to be using the 
program to its fullest potential.  While some of these barriers are linked to 
demographics, as addressed above, some of these barriers are structural or have 
other causes.  A very recent study from the HIV clinic in Alabama invited patients to 
participate in focus groups to determine barriers to adherence and to find out if any 
of these barriers are structural/programmatic in nature.24 Patients cited side effects, 
comorbid depression, pill fatigue, fear of toxicity, medication resistance, stigma, 
short time enrolled in ADAP, and problems with ADAP recertification as barriers.   
The clinic also determined that there may be some health literacy concerns that 
stemmed from the conversations, in which patients thought that side effects from 
the medication meant that the medication was not working.  Although this capstone 
will only be able to analyze the association between adherence and different 
demographics, programmatic and policy barrier will be important to consider. 
The second problem is that Medicaid expansion through the ACA could negatively 
affect HIV patients who will be newly eligible for Medicaid and no longer eligible for 
ADAP.  Since ADAPs offer additional retention services that should, theoretically, 
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increase medication adherence, the patients moving to Medicaid may be at a 
disadvantage.  This will be important to consider when determining the future of 
ADAPs in this changing healthcare environment.     
 
Methods 
 
In order to analyze the medication adherence of patients in KADAP and Kentucky 
Medicaid and to determine if any demographic factors are associated with 
medication non adherence, a retrospective, cross-sectional analysis of pharmacy 
claims data from the Kentucky Clinic Pharmacy as well as patient data from the 
Bluegrass Care Clinic, both located at the University of Kentucky, from one calendar 
year will be analyzed.  Adherence will be determined by the medication possession 
ratio (MPR) equation, discussed below.  Each patient will have an average MPR 
calculated from all of their claims data throughout the year.  An average MPR will 
also be calculated for KADAP and Medicaid.  In order to determine any demographic 
factors are associated with MPR, multivariate regression will be run with each 
demographic factor as an independent variable (age, sex, race, number of 
medications, income, and program) and MPR as the dependent variable.  Dummy 
variables will be created for program, sex, and race for regression purposes.  
Separate regressions will be run for KADAP and Medicaid together, KADAP alone, 
and Medicaid alone.   
 14 
Data Collection 
In this retrospective, cross-sectional analysis, pharmacy claims data from the 
Kentucky Clinic Pharmacy as well as patient data from the Bluegrass Care Clinic, 
both located at the University of Kentucky, were collected from January 1, 2011 to 
December 1, 2011.  Four separate sets of data were collected, and are shown below: 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 2: Values Contained in 
Medicaid Pharmacy Claims 
Medical record 
number 
Drug Name and 
Strength 
Dates of first 
and last fill 
Number of refills 
Days supply of 
each fill 
Age 
Gender  
Table 1: Values Contained in 
KADAP Pharmacy Claims 
KADAP ID 
number 
Drug Name 
and Strength 
Date of each 
fill 
Quantity filled 
Prescriber Drug Cost 
Age Race 
Gender  
Table 3: Values Contained in KADAP 
Clinic Data 
KADAP ID 
number 
Drug Name and 
Strength 
Date of each fill Quantity filled 
Prescriber Drug Cost 
Age Race 
Gender Income 
Insurance  
Table 4: Values Contained in 
Medicaid Clinic Data 
Medical Record Number Race 
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All data except for Medicaid pharmacy claims data had been compiled into excel documents 
by clinic staff or by the pharmacy claims process.  Medicaid pharmacy claims data were 
manually collected by the author by matching the medical record numbers provided by the 
clinic with patients in the pharmacy’s computer system.  KADAP pharmacy claims data 
were segregated by month, with the exception of demographics (race, age, and sex), which 
were reported quarterly.  The demographic data reported in January were used for the 
statistical analysis and assumed to be true for the entire year.  Data from pharmacy claims 
and from the Bluegrass Care Clinic were merged. When data overlapped, pharmacy claims 
data were used.  Since a list was not available for which patients were eligible for KADAP or 
Medicaid for the entire year, patients were assumed eligible based on the list generated by 
pharmacy claims data and the Bluegrass Care Clinic from the first quarter of the year.   
Inclusion and Exclusion Criteria 
 
Pharmacy claims data were included if the patient was at least 18 years old, was included 
on the KADAP ID number or Medicaid medical record number list provided by the clinic, if 
the medication was for an antiretroviral, if the medication was for at least a quantity of 15 
and assumed to be a 30-day supply, and if the patient filled one or more medications at 
least two times during the study period (the minimum requirement for the medication 
possession ratio equation).   
Pharmacy claims data were excluded if the number of days of supply could not be 
determined or if the KADAP ID number or medical record number were missing.   
Although KADAP requires that only 30 days of medication are given at a time, it was 
determined during analysis that there may have been cases when more than 30 days were 
given.  The author manually analyzed each claim and excluded the claims where the 
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number of days of supply was indeterminable.   For example, if a medication was written 
for a quantity of 15, the author looked at the refills to determine if they were refilled in 15-
day intervals or 30-day intervals.  If they were refilled in 15-day intervals, the data were 
excluded since calculations assumed each medication was filled for a 30-day supply.  
Several antiretrovirals rotate between once a day and twice a day dosing (a quantity of 30 
for 30 days versus a quantity of 60 for 30 days).  For these medications, the author 
manually assessed these claims to ensure that the medications found to rotate between a 
quantity of 30 and 60 are medications that are commonly prescribed this way (e.g. Norvir) 
before assuming that they were written for a 30-day supply.   
Medication Possession Ratio 
 
Adherence was determined based on the medication possession ratio, which was 
calculated using the following equation: 
                                                  
                                          
      
A medication possession ratio was calculated for each individual medication, and an 
average medication possession ratio was calculated for each patient by adding the 
percentage for each medication and dividing by the number of medications. For KADAP 
pharmacy claims data, the days supply was assumed to be 30 days for each medication, but 
claims were excluded if this information was indeterminable.  For Medicaid data, the days 
supply were readily available.  
For the numerator of the equation, the entire length of the prescription was assumed to be 
30 (the days supply) multiplied by the number of refills.  Therefore, if a patient refilled a 
prescription 3 times, the entire length of the prescription would be 90 days.  The length of 
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the last fill is always 30 days.  The medication possession ratio was calculated in Microsoft 
Excel. 
Statistical Analysis 
 
Once the average MPR was calculated in Excel, the data was transferred to Stata (version 
11).  Initially, descriptive statistics were calculated for the KADAP and Medicaid patients to 
determine baseline demographics.  
KADAP Demographics 
 
As shown in the table below, the majority of KADAP patients are white males and the total 
population consists of 2,024 patients.  
Table 5: Demographics of all KADAP Patients 
Race Frequency: 
Number of 
patients (% 
of total) 
Gender Frequency: 
Number of 
patients (% 
of total) 
White 1,233 (61%) Male 1,624 (80%) 
Black 633 (31%) Female 397 (19%) 
Hispanic 116 (6%) Unknown 3 (<1%) 
Other 42 (2%)   
Total 2,024 Total 2,024 
 
Looking further into the demographics of these KADAP patients (Table 6), the average 
salary of these patients is just under $7,000 per year, the average age is 45 years, and the 
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average number of antiretrovirals they take is three.  Of these patients, their average 
medication possession ratio is 84.7 perccent, with a range from 14.9 to 100 percent.  
 
Table 6: Mean Demographics of 
All KADAP Patients with Ranges 
MPR  84.7% (14.9%-
100%) 
Age 45 (21-79) 
Annual 
Income 
 
 
$6,770 ($0-$71,623) 
# of Meds 2.7 (1-9) 
   
Medicaid Demographics 
 
Listed in the below table are the baseline demographics of the Medicaid patients.  The 
majority of the eligible patients are black males, but the total number of patients in this 
group (n=55) is much smaller than that of the KADAP group.  
 
Table 7: Demographics of Included Medicaid Patients 
Race Frequency: 
Number of 
patients (% 
of total) 
Gender Frequency: 
Number of 
patients (% 
of total) 
White 23 (42%) Male 33 (60%) 
Black 31 (56%) Female 22 (40%) 
Amer. 
Indian 
1 (2%)   
Total 55 Total 55 
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KADAP Regression Analysis 
 
Multivariate regression analysis was done for the KADAP data to determine if patient 
demographic factors, including age, race, sex, annual income, and number of antiretrovirals 
taken influence the average medication possession ratio.  The regression output is shown 
in the table below. 
Table 8: Multivariate Regression for KADAP MPR 
Variable Coefficient Standard Error t P>|t| 95% Confidence Interval 
Age 0.12128 0.03896 3.11 0.002 [0.04487-0.1976955] 
Income 0.00002 0.00004 0.54 0.59 [-0.00006-0.000102] 
Count -0.43416 0.30195 -1.44 0.151 [-1.02634-0.158006] 
Black Race -3.7394 0.88369 -4.23 0.000 [-5.47247- -2.00638] 
Male Sex 1.6702 1.03005 1.62 0.105 [-0.34984-3.69032] 
 R2=0.0189; n=2,024 
 
Medicaid Regression Analysis 
 
Multivariate regression analysis was done for the Medicaid data to determine if patient 
demographic factors, including age, race, sex, and number of antiretrovirals taken (count) 
influence the average medication possession ratio.  The regression output is shown in the 
table below. 
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Table 9: Medicaid Regression Output 
Variable Coefficient P-value 95% Confidence Interval 
Age 0.106 0.740 [-0.5315-0.7431] 
Male Sex 11.055 0.114 [-2.7336-24.8427] 
Black Race 3.014 0.963 [-9.1561-15.1841] 
Count -0.1573 0.963 [-6.866-6.5515] 
Medicaid and KADAP Regression Analysis  
 
Multivariate regression analysis was done for Medicaid and KADAP combined data to 
determine if patient demographic factors, including age, race, sex, program, and number of 
antiretrovirals taken (count) influence the average medication possession ratio.  The 
regression output is shown in the table below. 
Table 10: Multivariate Regression for KADAP and Medicaid MPR 
Variable Coefficient Standard 
Error 
t P>|t| [95% Confidence 
Interval] 
Age 0.127 0.03819 3.33 0.001 [0.052189-
0.201986] 
Count -0.4334 0.30192 -1.44 0.151 [-1.05507-
0.158682] 
Black Race -3.8368 0.87273 -4.40 0.000 [(-5.54832)-(-
2.125297)] 
Male Sex 2.0242 1.01655 1.99 0.047 [0.030617- 
4.017748] 
Medicaid -6.1956 2.5043 -2.47 0.000 [(-11.10686)-(-
1.284331)] 
 R2=0.0241; n=2,079 
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Results 
Kentucky AIDS Drug Assistance Program  
MPR 
The average MPR for KADAP patients is 84.7 percent.  As depicted in Figure 1, over half of 
the patients in KADAP had medication possession ratios between 91-100 percent.  The rest 
of the patients are distributed throughout other ranges, with 11.9 percent of patients 
having an MPR of 0-60 percent, 7.9 percent of patients having an MPR of 61-70 percent, 
10.2 percent of patients having an MPR of 71-80 percent, and 18 percent of patients having 
an MPR of 81-90 percent.  
 
 
Age 
 
As shown in Table 8, the medication possession ratio was significantly associated with age 
in regression analysis (p=0.002) in which every 1-year increase in age was associated with 
0.121 percent increase in MPR.  When age is broken into age groups, starting with the 
youngest group within the patient population, the increased average medication 
0.00%
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Figure 1: Distribution of MPR for 
KADAP 
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possession ratio seen with the older decade ranges (50-59, 60-69, and 70-79 years) is 
visible graphically (Figure 2).  The average MPR decreases slightly with the oldest age 
range, but this is most likely related to the small number of patients depicted in this decade 
(n=25).  
 
Race 
 
When stratified by race (Figure 3), the average medication possession ratio is 85.9 percent 
for white patients, 81.8 percent for black patients, 85.8 percent for Hispanic patients, and 
89.6 percent for other patients, which includes mixed-race patients.  In multivariate 
analysis, race and medication possession ratio are associated in a statistically significant 
manner (p<0.0001) with black patients having average MPR’s 3.739 percent lower than 
other races (dummy variables 0=non-black, 1=black).  
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Figure 2: Average MPR for KADAP 
Patients Per Age Group  
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Sex 
 
Although sex was not statistically significant in multivariate analysis (p=0.105; dummy 
variables 0=non-male, 1=male), it was significant in univariate analysis with male gender 
having a 2.83 percent increase in average MPR (p=0.011).    
Count and Income 
 
Neither the number of antiretrovirals the patient takes nor their income was significantly 
associated with MPR (p=0151 and p=0.59, respectively).  
Location 
 
Since patients who do not live in Lexington have their medications mailed to them, the 
average medication possession ratio of Bluegrass Care Clinic patients (Lexington) were 
compared to patients outside of the Bluegrass Care Clinic (assumed to be non-Lexington).  
There was not a statistically significant difference between the two sets of patients (85.9 
percent Lexington, 84.4 percent non-Lexington; p=0.128).  
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Figure 3: Average MPR for KADAP Patients by 
Race 
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Medicaid 
MPR 
 
The average MPR for Medicaid patients was 77.3 percent. When the medication possession 
ratios are distributed among groups (0-60 percent, 61-70 percent, 71-80 percent, 81-90 
percent, 91-100 percent), 40 percent of patients have a medication possession ratio of 91 
percent to 100 percent and one quarter of patients have an MPR of 0-60 percent (Figure 4).   
However, similar to the KADAP patients, most patients fell into the 91-100 percent MPR 
category.  
 
 
Other Variables 
 
Unlike with the KADAP patient variables, none of the Medicaid variables were statistically 
significantly associated with MPR in regression analysis (Table 9).  However, this may be 
due to the very small number of patients in this category.   
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Kentucky AIDS Drug Assistance Program and Medicaid 
Program  
 
When data from Medicaid and KADAP are combined for regression (Table 10), program 
status is a statistically significant variable (p=0.000; dummy variable 0=KADAP, 
1=Medicaid) in which Medicaid is associated with a 6.2 percent decease in average MPR.   
Sex 
Unlike with KADAP alone, in this analysis, sex is also statistically significant (p<0.047) with 
the male sex being associated with a 2.02 percent increase in average MPR compared to 
non-male. 
Age 
Similar to the KADAP regression analysis, age is statistically significant (p<0.001) with each 
additional year increasing the average MPR by 0.13 percent.  
Race 
Similar to the KADAP regression analysis, age is statistically significant (p=0.000) with 
black race being associated with a 3.84 percent decrease in average MPR.  
Count 
Similar to the previous analyses, the number of antiretrovirals the patient took was not 
statistically significant (p<0.151).  
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Discussion 
Kentucky AIDS Drug Assistance Program 
 
As shown above, age and race were significantly correlated with a lower average MPR, with 
younger, black patients having lower average MPRs than their counterparts.  This is 
consistent with a study from a similar ADAP in Alabama13 as well as with other adherence 
studies that focused specifically on HIV patients.  However, with an average MPR of 85 
percent, many patients within the program still fall below the optimal adherence level of 95 
percent for viral load suppression, putting them at greater risk of developing medication 
resistance, transmitting the disease, contracting opportunistic infections, and becoming 
hospitalized.  Additionally, Alabama found that 23 percent of the medications did not reach 
the intended ADAP enrollees13.  Although the administrative costs of filling these 
medications has not been quantified, time and money from pharmacists, pharmacy 
technicians, social workers, and various ADAP administrators were wasted without getting 
the medication to the intended patient.   
Medicaid 
 
There were no significant relationships between age, race, sex, or medication count and 
MPR for Medicaid patients.  Due to the small sample, this study should be repeated with a 
larger sample size, possibly through Medicaid third-party claims data, to insure adequate 
power to detect a statistically significant relationship.  However, when Medicaid and 
KADAP data were combined for regression, Medicaid was associated with a statistically 
significant 6 percent decrease in MPR.  Although a larger sample size is needed to make 
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significant recommendations, this could show that Medicaid patients as a whole are at a 
disadvantage for adherence and program utilization when compared to KADAP patients.  
This is due to the increased amount of support given to KADAP patients – a dedicated 
pharmacist, pharmacy technician, and in house care coordinators/social workers – as well 
as the requirement to stay involved with the program as eligibility criteria.  Medicaid 
patients do not have the same access to these support services or incentives to become and 
remain adherent.   
Recommendations 
Programmatic and Policy Implications 
Programmatic Barriers to Adherence 
 
To ensure that patients are fully utilizing these public programs and being adherent to 
their HIV medications, it is necessary to make changes within each program that will 
promote medication adherence.  Since the analysis shows that younger, black patients are 
more likely to be nonadherent, initial programmatic changes should be focused on these 
patients. For KADAP, an easy change that could increase adherence is to make refill 
reminder calls with call lists stratified by age and race so that the patients more likely to be 
nonadherent (younger, black patients) will be the focus.  Refill reminder call lists are a 
practice that is already done by some chain retail pharmacies, in which a daily list of 
patients who are due for a refill is generated.  A pharmacy technician calls all patients on 
the list to remind them that they are due for a refill.  Although this may not help patients 
who simply forget to take their medications or have other reasons for being nonadherent, it 
could help patients who forget to get their medications refilled.  This could also increase 
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the conversation between pharmacy personnel and the patient, helping to determine the 
root cause of the patient’s nonadherence.  While this would take time away from a 
pharmacy personnel’s daily duties, this could be easily done by an unpaid intern 
pharmacist and would take minimal time if a call list could be generated by the computer 
system.  
Barriers Created by the Affordable Care Act and Medicaid Expansion 
 
Based on the analysis in which KADAP patients have statistically significantly higher MPRs, 
it may be necessary to alter the requirements for Medicaid and KADAP co-enrollment in 
order to ensure medication adherence within Medicaid.  Since many KADAP patients will 
be newly eligible for Medicaid due to Medicaid expansion with the ACA, these patients will 
lose the added retention and adherence programs afforded to them by KADAP.  As shown 
in the analysis, patients enrolled in Medicaid have lower adherence rates than KADAP 
patients, and studies have shown that public insurance is associated with two times the 
mortality rate at one year when compared with private insurance and no insurance HIV 
populations26.  While patients can currently be enrolled in both programs, KADAP typically 
functions as a “safety net” to cover medication copays.  However, copay assistance may not 
be a main barrier to medication adherence for Medicaid patients.  Since these patients 
benefit from the additional services KADAP offers, a new policy that allows patients to be 
covered by Medicaid while still receiving services from KADAP regardless of financial need 
may be warranted.  This would also be a more cost-effective and efficient option than 
implementing these services newly in Medicaid. 
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Other Programmatic and Policy-Related Barriers to Adherence 
 
As previously discussed, a recent study from the HIV clinic in Alabama24 invited ADAP 
patients to participate in focus groups to determine barriers to adherence and to find out if 
any of these barriers are structural/programmatic in nature.  Patients cited side effects, 
comorbid depression, pill fatigue, fear of toxicity, medication resistance, stigma, short time 
enrolled in ADAP, and problems with ADAP recertification as barriers.   The clinic also 
determined that there may be some health literacy concerns that stemmed from the 
conversations, in which patients thought that side effects from the medication meant that 
the medication was not working.  Since there appears to be programmatic similarities 
between the ADAP in Alabama and KADAP, these findings generate ideas for programmatic 
and policy changes that could be helpful to both programs.  From a programmatic 
standpoint, it could be beneficial to have a mandatory “HIV 101” class for newly enrolled 
patients.  This one-time class could address the basics of HIV, how the medications work, 
the importance of taking medications appropriately, and complications from medication 
nonadherence.  This class could be run by pharmacy residents and count as part of their 
mandatory teaching component.  Depending on the frequency, this could also be facilitated 
by clinic pharmacists who have a specific interest in HIV care.  A pilot program study would 
be needed to determine the utility of such a program in HIV patients.   
Since many patients cited depression as a barrier to adherence, and depression and 
HIV/AIDS tend to be comorbid, having dedicated psychiatric support with counselors could 
aid these patients in becoming adherent and living fulfilled lives.  This cost could be 
significant to the program, as a full-time counselor makes $40,000 annually on average25.  
However, depending on the change in medication adherence that could come from 
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counseling services, this cost may be justified.  A pilot program study would be needed to 
determine this utility.   
From a policy standpoint, many patients in the Alabama study stated that the 
recertification process was a burden and paperwork sometimes got lost within the system, 
increasing time for recertification.  Anecdotally, this is also a problem that has occurred 
with KADAP.  Some patients stated that they had been dropped from the program and did 
not realize it until they went to pick their medications up from the pharmacy.  With 
increased use of technology in healthcare, computerizing this process could be beneficial 
for this program.  While this would be a costly endeavor, having the capability to upload 
documents to a website, check ADAP status, and allow patients and social workers to 
communicate regarding program eligibility questions could make the process more 
efficient.  Patients cited having limited access to transportation, making it difficult to come 
to the clinic when there were recertification and eligibility problems.  Having a website to 
upload documents and update information could decrease the need for costly 
transportation for patients.   
Limitations 
 
This study has several limitations that require discussion.  First, since the days supply of 
medications in the original data obtained was not always easily determined, errors could 
have been made in assuming that medications were intended for 30 days.  Additionally, 
many medications were excluded when the days supply could not be determined.  These 
issues typically happened with only a few medications, which could create bias by 
removing several pieces of data for the same medication.  Additionally, it is unknown 
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whether these patients were enrolled in KADAP for the entire year.  Some patients could 
have gained insurance for part of the year and then re-enrolled in KADAP, making their 
MPR falsely low.   
The MPR calculation itself has limitations.  First, it is unknown whether the patient picked 
up the medication on the day the claim was processed.  Medications are not reprocessed 
unless they have been not picked up for 10 days.  Additionally, the patient having the 
medication on-hand does not mean that they will take it daily as prescribed, so the MPR 
may not always accurately reflect the patient’s adherence.   
Additionally, only a small number of Medicaid patients were eligible for the study since 
they had to both see a prescriber at the Bluegrass Care Clinic and fill their medications at 
the Kentucky Clinic Pharmacy.  For the patients who did fit these criteria, they may have 
filled their medications at a different pharmacy throughout the year, making their MPR 
falsely low.  Additionally, these patients could have been eligible for KADAP throughout the 
year, making it difficult to analyze Medicaid as a separate entity from KADAP. 
Lastly, there are other factors that are not associated with any of the variables studied that 
could affect a patient’s medication adherence, such as comorbid conditions, level of 
education, length of time in the program, family support, transportation, housing, and 
drug/alcohol dependence.  Many of these factors have been studied in the literature and 
could contribute to medication nonadherence.  
Conclusions 
Most patients enrolled in KADAP do not reach the 95 percent adherence rate necessary for 
optimal viral suppression.  However, on average, the studied Medicaid patients had a 
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significantly lower MPR than patients enrolled in KADAP.  In order to increase adherence in 
both programs, changes need to be made to decrease barriers to adherence, including refill 
reminders, HIV classes for new KADAP enrollees, increased access to psychiatric and 
counseling services, online access, and requirement changes for Medicaid and KADAP co-
enrollment.   
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